SUDARSHANSpecialty Chemicals
Sudarshan Pharma Industries Ltd — Profit & Loss Statement
₹24.24
+5.48%
Sudarshan Pharma Industries Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.74 Cr | 0.00 | -0.06 Cr | -0.03 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.25 | 0.26 | 0.26 | — |
| Normalized EBITDA | 42.44 Cr | 25.42 Cr | 15.23 Cr | 10.86 Cr | — |
| Total Unusual Items | -2.82 Cr | 0.00 | -0.24 Cr | -0.10 Cr | — |
| Total Unusual Items Excluding Goodwill | -2.82 Cr | 0.00 | -0.24 Cr | -0.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 15.96 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Reconciled Depreciation | 2.22 Cr | 1.24 Cr | 0.91 Cr | 0.87 Cr | — |
| Reconciled Cost Of Revenue | 439.76 Cr | 422.48 Cr | 431.61 Cr | 336.55 Cr | — |
| EBITDA | 39.62 Cr | 25.42 Cr | 14.99 Cr | 10.76 Cr | — |
| EBIT | 37.40 Cr | 24.17 Cr | 14.08 Cr | 9.89 Cr | — |
| Net Interest Income | -15.77 Cr | -8.94 Cr | -4.91 Cr | -3.18 Cr | — |
| Interest Expense | 15.77 Cr | 8.94 Cr | 4.59 Cr | 2.76 Cr | — |
| Normalized Income | 18.03 Cr | 11.46 Cr | 7.21 Cr | 5.32 Cr | — |
| Net Income From Continuing And Discontinued Operation | 15.96 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Total Expenses | 467.35 Cr | 441.97 Cr | 446.91 Cr | 346.95 Cr | — |
| Diluted NI Availto Com Stockholders | 15.96 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Net Income Common Stockholders | 15.96 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 15.96 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Minority Interests | 33000.00 | 0.00 | 0.00 | -7000.00 | — |
| Net Income Including Noncontrolling Interests | 15.95 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | — | — |
| Net Income Continuous Operations | 15.95 Cr | 11.46 Cr | 7.04 Cr | 5.25 Cr | — |
| Tax Provision | 5.68 Cr | 3.77 Cr | 2.46 Cr | 1.89 Cr | — |
| Pretax Income | 21.63 Cr | 15.23 Cr | 9.50 Cr | 7.14 Cr | — |
| Other Non Operating Income Expenses | 2.52 Cr | 2.61 Cr | 0.61 Cr | 0.25 Cr | — |
| Special Income Charges | -2.82 Cr | 0.00 | -0.24 Cr | -0.10 Cr | — |
| Net Non Operating Interest Income Expense | -15.77 Cr | -8.94 Cr | -4.91 Cr | -3.18 Cr | — |
| Interest Expense Non Operating | 15.77 Cr | 8.94 Cr | 4.59 Cr | 2.76 Cr | — |
| Operating Income | 37.70 Cr | 21.57 Cr | 14.42 Cr | 10.15 Cr | — |
| Operating Expense | 27.59 Cr | 19.49 Cr | 15.30 Cr | 10.39 Cr | — |
| Other Operating Expenses | 20.48 Cr | 14.61 Cr | 7.77 Cr | 4.73 Cr | — |
| Depreciation And Amortization In Income Statement | 2.22 Cr | 1.24 Cr | 0.91 Cr | 0.87 Cr | — |
| Depreciation Income Statement | 2.22 Cr | 1.24 Cr | 0.91 Cr | 0.87 Cr | — |
| Gross Profit | 65.29 Cr | 41.06 Cr | 29.72 Cr | 20.54 Cr | — |
| Cost Of Revenue | 439.76 Cr | 422.48 Cr | 431.61 Cr | 336.55 Cr | — |
| Total Revenue | 505.05 Cr | 463.54 Cr | 461.33 Cr | 357.09 Cr | — |
| Operating Revenue | 505.05 Cr | 463.54 Cr | 461.33 Cr | 357.09 Cr | — |
| Interest Income | — | 0.79 Cr | 0.49 Cr | 0.20 Cr | 0.03 Cr |
| Rent Expense Supplemental | — | 0.74 Cr | 0.58 Cr | 0.58 Cr | 0.44 Cr |
| Diluted Average Shares | — | 24.37 Cr | 12.85 Cr | 24.07 Cr | 24.07 Cr |
| Basic Average Shares | — | 23.87 Cr | 12.85 Cr | 24.07 Cr | 24.07 Cr |
| Diluted EPS | — | 0.47 | 0.55 | 0.55 | 0.11 |
| Basic EPS | — | 0.48 | 0.55 | 0.55 | 0.11 |
| Total Other Finance Cost | — | 1.07 Cr | 0.82 Cr | 0.62 Cr | 0.37 Cr |
| Interest Income Non Operating | — | 0.79 Cr | 0.49 Cr | 0.20 Cr | 0.03 Cr |
| Selling General And Administration | — | 4.08 Cr | 3.04 Cr | 1.79 Cr | 1.24 Cr |
| Selling And Marketing Expense | — | 0.38 Cr | 0.64 Cr | 0.65 Cr | 0.37 Cr |
| General And Administrative Expense | — | 3.70 Cr | 2.41 Cr | 1.14 Cr | 0.87 Cr |
| Rent And Landing Fees | — | 0.74 Cr | 0.58 Cr | 0.58 Cr | 0.44 Cr |
| Other Special Charges | — | — | 0.24 Cr | 0.10 Cr | — |
| Preferred Stock Dividends | — | — | — | — | 0.00 |
| Net Income Extraordinary | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sudarshan Pharma Industries Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.